The US Food and Drug Administration has ordered manufacturers of GLP-1 diabetes and obesity drugs — including Ozempic, Wegovy, Mounjaro and Zepbound — to add a label warning about a rare optic nerve disease that can cause permanent vision loss. The decision, announced by the regulator, follows an analysis of 126 randomized clinical trials involving more than 134,000 people.

The condition at issue is non-arteritic anterior ischemic optic neuropathy, or NAION. Disrupted blood supply to the optic nerve drives the disease, which can cause sudden and usually painless vision loss in one eye, including permanent blindness.

What do the trial numbers show?

The FDA's analysis found a measurable gap in incidence. Among patients receiving GLP-1 drugs, NAION occurred at 6.4 cases per 100,000 patient-years, against 3.8 cases per 100,000 patient-years in control groups — roughly 1.7 times the rate. Across all the studies, researchers identified 15 probable cases in total: ten among patients taking GLP-1 drugs and five in control groups.

The FDA itself stresses that this is a very rare complication. Data from observational studies point to a possible increase in risk, but the exact biological mechanism behind the association has not been established. The observed statistical effect alone does not mean that each drug directly damages the optic nerve, the regulator noted.

How should patients respond?

The FDA advises patients to seek immediate medical attention if they experience sudden deterioration in vision, blind spots, color disturbances or blurred vision. Where NAION is suspected, an urgent examination by an ophthalmologist is necessary. Patients should make any decision to stop taking the drug together with their doctor, not on their own.

The regulator did not demand that use of the drugs cease. Its action is limited to adding warnings about the possible risk to product labeling.

What did the manufacturers say?

Novo Nordisk, maker of Ozempic and Wegovy, said available scientific evidence does not prove a cause-and-effect relationship between semaglutide — the active ingredient in both products — and optic nerve damage. Eli Lilly, which makes Mounjaro and Zepbound, said it is studying the new FDA requirements.

Why does this matter commercially?

Drugs in the GLP-1 family are widely used to control blood sugar levels in type 2 diabetes and to reduce body weight, making them among the highest-revenue pharmaceutical products on the market. A new warning on that scale of prescribing base reaches a population measured in millions of patient-years of exposure.

The FDA's framing is deliberate: a rare complication, an unproven mechanism, and no withdrawal from the market. For Novo Nordisk and Eli Lilly, the immediate cost is a label change rather than a sales prohibition — but the warning lands on the two product families that anchor their growth.

The 15 identified cases sit inside a trial population of more than 134,000 people.